Investigational drugs for treating major depressive disorder

@article{Dhir2017InvestigationalDF,
  title={Investigational drugs for treating major depressive disorder},
  author={Ashish Dhir},
  journal={Expert Opinion on Investigational Drugs},
  year={2017},
  volume={26},
  pages={24 - 9}
}
  • A. Dhir
  • Published 2 January 2017
  • Psychology
  • Expert Opinion on Investigational Drugs
ABSTRACT Introduction: Treatment of patients suffering from major depression could be highly challenging for psychiatrists. Intractability as well as relapse is commonly seen among these patients, leading to functional impairment and poor quality of life. The present review discusses some of the novel investigational drugs that are under pre-clinical or clinical phases in the treatment of major depression. Areas covered: Molecules belonging to different classes such as triple reuptake… 
International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets
TLDR
It is suggested that drug targeting different neurobiological systems should be able to restore normal function but must also promote resilience to reduce the long-term vulnerability to recurrent depressive episodes.
The preclinical discovery and development of agomelatine for the treatment of depression
TLDR
There is now evidence supporting the clinical efficacy and safety profile of agomelatine in the acute-phase treatment of MDD, and findings of post-marketing research on safety, efficacy, and cost-effectiveness of the drug are examined.
The use of antidepressants in oncology: a review and practical tips for oncologists
TLDR
ADs are a relatively safe and effective treatment for more severe major depression in cancer patients and more research is urgently needed regarding the efficacy of ADs in different cancer types and cancer settings, their interactions with anticancer agents and their additive benefit when integrated with psychosocial interventions.
Bipolar depression: a major unsolved challenge
TLDR
Evidence is emerging of short-term efficacy of several modern antipsychotics (including cariprazine, lurasidone, olanzapine-fluoxetine, and quetiapine) for bipolar depression, including with mixed features, though they risk adverse metabolic and neurological effects.
Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
TLDR
The neurotrophic mechanisms of antidepressants are described and current and novel treatment modalities that can restore neural circuit function by directly engaging neuroplasticity are described.
Unmet Needs in Psychiatry: Bipolar Depression
TLDR
For bipolar depression, evidence of efficacy of mood-stabilizing agents, including lithium and several anticonvulsants (except lamotrigine, long-term) remains limited; emerging use of modern antipsychotics is encouraging for short-term treatment of acuteipolar depression, especially with mixed features.
Preclinical Models for Assessment of Antidepressant Abuse Potential
TLDR
Increasing extracellular dopamine may both increase antidepressant efficacy and reduce sexual dysfunction, but it increases abuse potential.
Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule
TLDR
This review examines the current understanding of the roles of endogenous and exogenous sources of glutamate and the glutamatergic system in the aetiology, progression and management of depression, and examines the relationships that link the gut-brain axis, glutamate and depression.
Psychoendocrinology: Arginine Vasopressin and Resilience in Patients with Major Depressive Disorder.
TLDR
AVP levels are indeed higher in patients struggling with major depressive disorder and psychological hardiness was decreased in patients with MDD compared with healthy controls, and there was a negative correlation between plasma AVP level and psychological hardness, reflecting lower stress resilience.
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
TLDR
This review summarized the role of neuroplasticity in the occurrence and development of the two disorders in question and explored individualized application strategies of analgesic drugs and antidepressants that have different pharmacological effects in the treatment of chronic pain-induced depression.
...
1
2
...

References

SHOWING 1-10 OF 145 REFERENCES
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
TLDR
Clinical evidence supporting the use of glutamate receptor modulators with direct affinity for cognate receptors is reviewed, including non-competitive NMDA receptor antagonists (ketamine, memantine, dextromethorphan, AZD6765), and theoretical glutamate receptor targets with preclinical antidepressant-like efficacy.
Major Depressive Disorder and Kappa Opioid Receptor Antagonists
TLDR
It will be not surprising to predict the potential success of ALKS 5461 (a combination of buprenorphine and ALKS-33) in the near future and CERC-501 will be expected to be available as monotherapy or adjuvant therapy with other first-line antidepressants in the treatment of TRD, if ongoing clinical trials continue to provide positive benefit-risk profiles.
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review
TLDR
Current efforts are focused on extending ketamine’s antidepressant efficacy, uncovering the neurobiological mechanisms responsible for ketamine's antidepressant activity in biologically enriched subgroups, and identifying treatment response biomarkers to personalize antidepressant selection.
Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5
TLDR
The current article reports on the preclinical and clinical work with basimglurant which strongly supports its use for treatment of depression, and covers the pharmacodynamics, pharmacokinetics and safety and tolerability features of basimGlurant together with its clinical efficacy in a clinical type II trial.
Glutamate-Based Drug Discovery for Novel Antidepressants
TLDR
The results of research showing that metabotropic glutamate (mGlu) receptors could be the target of novel antidepressants are presented, which may lead to a new understanding of the biological basis of depression.
Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review
  • M. Pompili, G. Serafini, P. Girardi
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2013
TLDR
Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C antagonist, has been reported to be effective as antidepressant drug and enhances neuroplasticity mechanisms and adult neurogenesis in brain areas such as hippocampus and prefrontal cortex.
Ketamine and other glutamate receptor modulators for depression in adults.
TLDR
Among all glutamate receptor modulators, only ketamine (administered intravenously) proved to be more efficacious than placebo, though the quality of evidence was limited by risk of bias and small sample sizes.
Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
The Kappa Opioid Receptor: From Addiction to Depression, and Back
TLDR
A large body of evidence from preclinical models indicating that the kappa opioid receptor (KOR), a member of the opioid neuromodulatory system, represents a central player in the regulation of both reward and mood processes is summarized.
Ketamine followed by memantine for the treatment of major depression.
TLDR
The first case of a patient suffering from major depressive disorder (MDD) treated successfully by a two-step therapeutic regimen consisting of two infusions of ketamine followed by oral administration of memantine is reported.
...
1
2
3
4
5
...